Tevogen Inc.
TVGN Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 23, 2026
$6.53
KIRA · Stoqly’s AI analyst, in plain words
- Tevogen Inc. had −$0.2M of revenue in fiscal 2025.
- Its operating margin was 13,364.3%, down 15,746.9 pts: of every 100 in sales, about 13,364 is left after running the business.
- Tevogen Inc. lost $26.3M in fiscal 2025.
- Free cash flow was −$12.4M in fiscal 2025, 6,335.9% of revenue.
Market cap
$25.0M
P/E
—
Revenue
−$0.2M
Net income
−$26.3M
Free cash flow
−$12.4M
Operating margin
13,364.3%
Tevogen Inc. in 30 seconds · fiscal 2025
Does it make a profit?
13,433.2%
No. It lost money last year.
Does profit turn into cash?
6,335.9%
Yes. 6,335.9% of sales ends up as free cash.
How healthy are the accounts?
2 / 7
Weak. It passes 2 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Tevogen Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 31, 2026
- Legal name
- Tevogen Inc.
- CIK
- 0001860871
Tevogen Inc. · TVGN
Results and finances
The last 4 fiscal years. Amounts in USD.
| Fiscal year | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Sales and profit | ||||
| Revenue | — | — | −$0.2M | −$0.2M |
| Net interest income | — | — | −$0.2M | −$0.2M |
| Operating margin | — | — | 29,111.1% | 13,364.3% |
| Net income | $4.4M | −$60.5M | −$13.7M | −$26.3M |
| Net margin | — | — | 7,460.5% | 13,433.2% |
| Diluted EPS | — | −$2.44 | −$3.50 | −$8.08 |
| Cash | ||||
| Cash from operations | −$0.2M | −$8.2M | −$12.0M | −$12.3M |
| Capital expenditure | — | $0.1M | — | $0.1M |
| Free cash flow | — | −$8.3M | — | −$12.4M |
| FCF margin | — | — | — | 6,335.9% |
| Share buybacks | — | $343M | — | — |
| Share count change | — | — | −88.1% | 13.2% |
| Debt and strength | ||||
| Cash and short-term investments | $0.1M | $0.0M | $0.0M | $0.0M |
| Debt incl. finance leases | $0.0M | — | — | — |
| Shareholders' equity | −$34.0M | −$94.4M | −$6.7M | −$8.2M |
| Current ratio | 0.8x | 0.0x | 0.3x | 0.2x |
| Interest coverage | — | −7.3x | −291.1x | — |
| Returns and quality | ||||
| Piotroski F-score | — | — | — | 2 |
| Altman Z'' | — | −170.6 | −224.1 | −152.9 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
1 insider
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Tevogen Inc. · TVGN
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $6.53 a share, the company is worth $25.0M.
Source: SEC EDGAR XBRL filings (CIK 0001860871). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.